SEC 13F Intelligence

Managers / Q1 2024 · view latest →

Exome Asset Management LLC

CIK 0002011932 · 330 MADISON AVENUE, NEW YORK, NY, 10017 · 212-403-3900

Reported Value
$117M
Q1 2024
Positions
53
Filings on Record
14
2019–present window
Filed
May 15, 2024
original filing

Summary

Exome Asset Management LLC reported $117M in U.S.-listed holdings across 53 positions for Q1 2024.

Its largest position, LLY, represents 6.5% of the portfolio.

Compared with Q4 2023, the fund opened 28 new positions and exited 27.

Portfolio Metrics

Turnover
+42.9%
vs prior filed quarter
Top-10 Concentration
+40.0%
share of reported value
Largest Position
+6.5%
Eli Lilly
New / Exited
28 / 27
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’23: $101MQ4 ’23Q1 ’24: $117MQ2 ’24: $115MQ2 ’24Q3 ’24: $146MQ4 ’24: $133MQ4 ’24Q1 ’25: $112MQ2 ’25: $135MQ2 ’25Q3 ’25: $165MQ4 ’25: $209MQ4 ’25Q1 ’26: $193Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 76.8%ADR: 17.2%Other: 6.0%
  • Common Stock · 76.8% · $90M
  • ADR · 17.2% · $20M
  • Other · 6.0% · $7M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
RNAGBPAVIDITY BIOSCIENCES INCNEW+135.2K135.2K+$3M$3M
CRBPCORBUS PHARMACEUTICALS HLDGSNEW+87.8K87.8K+$3M$3M
260CENTESSA PHARMACEUTICALS PLCNEW+274.9K274.9K+$3M$3M
AEROVATE THERAPEUTICS INCNEW+98.5K98.5K+$3M$3M
MOR2MORPHOSYS AGNEW+154.8K154.8K+$3M$3M
KRYSKRYSTAL BIOTECH INCNEW+14.7K14.7K+$3M$3M
INOZYME PHARMA INCNEW+273.4K273.4K+$2M$2M
ELEVATION ONCOLOGY INCNEW+369.3K369.3K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2024

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LLYELI LILLY & COhistory →COM6.46%$8M9.7K
2DR REDDYS LABS LTDADR5.40%$6M86.0K
3ONCBEIGENE LTDhistory →SPONSORED ADR4.93%$6M36.8K
4CITHE CIGNA GROUPhistory →COM4.76%$6M15.3K
5NVLSEURALPINE IMMUNE SCIENCES INChistory →COM3.97%$5M117.0K
6TGTXTG THERAPEUTICS INChistory →COM3.00%$4M230.3K
7RNAGBPAVIDITY BIOSCIENCES INChistory →COM2.95%$3M135.2K
8CRBPCORBUS PHARMACEUTICALS HLDGShistory →COM NEW2.95%$3M87.8K
9DC4DEXCOM INChistory →COM2.95%$3M24.8K
10260CENTESSA PHARMACEUTICALS PLChistory →SPONSORED ADS2.66%$3M274.9K
11TCE2CELLDEX THERAPEUTICS INC NEWhistory →COM NEW2.56%$3M71.1K
12GONGERON CORPhistory →COM2.51%$3M886.8K
13AEROVATE THERAPEUTICS INCCOM2.49%$3M98.5K
14MOR2MORPHOSYS AGhistory →SPONSORED ADS2.40%$3M154.8K
15TVTXTRAVERE THERAPEUTICS INChistory →COM2.39%$3M362.5K
16KRYSKRYSTAL BIOTECH INChistory →COM2.24%$3M14.7K
17ISRGINTUITIVE SURGICAL INChistory →COM NEW2.17%$3M6.4K
18TARSTARSUS PHARMACEUTICALS INChistory →COM2.06%$2M66.3K
19MDGLMADRIGAL PHARMACEUTICALS INChistory →COM1.81%$2M7.9K
20INOZYME PHARMA INCCOM1.79%$2M273.4K
21RYTMRHYTHM PHARMACEUTICALS INChistory →COM1.69%$2M45.6K
22IM8NINSMED INChistory →COM PAR $.011.67%$2M71.7K
23ELEVATION ONCOLOGY INCCOM1.62%$2M369.3K
24EXKEXACT SCIENCES CORPhistory →COM1.58%$2M26.7K
25CYTKCYTOKINETICS INChistory →COM NEW1.56%$2M26.0K
26RGNXREGENXBIO INChistory →COM1.52%$2M84.5K
27BIIBBIOGEN INChistory →COM1.51%$2M8.2K
28OCULOCULAR THERAPEUTIX INChistory →COM1.51%$2M193.6K
29AGIOAGIOS PHARMACEUTICALS INChistory →COM1.50%$2M59.9K
30NTRANATERA INChistory →COM1.46%$2M18.6K
31PENPENUMBRA INChistory →COM1.41%$2M7.4K
32GHGUARDANT HEALTH INChistory →COM1.40%$2M79.0K
33OLMAOLEMA PHARMACEUTICALS INChistory →COM1.39%$2M143.4K
34ARWRARROWHEAD PHARMACEUTICALS INhistory →COM1.36%$2M55.7K
35BBIOBRIDGEBIO PHARMA INChistory →COM1.29%$2M48.8K
36430TERNS PHARMACEUTICALS INChistory →COM1.28%$1M227.8K
37MARINUS PHARMACEUTICALS INCCOM NEW1.26%$1M163.1K
38INARI MED INCCOM1.24%$1M30.1K
39QTRXQUANTERIX CORPhistory →COM1.20%$1M59.6K
40ITCIEURINTRA-CELLULAR THERAPIES INChistory →COM1.20%$1M20.3K
41SWAVUSDSHOCKWAVE MED INChistory →COM1.12%$1M4.0K
42VYNEVYNE THERAPEUTICS INChistory →COM1.09%$1M415.4K
43RGLSREGULUS THERAPEUTICS INCCOM0.99%$1M402.5K
44QTTBQ32 BIO INCCOM0.95%$1M65.0K
45ZLABZAI LAB LTDADR0.90%$1M65.3K
46ELVNENLIVEN THERAPEUTICS INCCOM0.87%$1M57.6K
47VTYXUSDVENTYX BIOSCIENCES INCCOM0.77%$901,571163.9K
48RAREULTRAGENYX PHARMACEUTICAL INCOM0.71%$831,08217.8K
49NBPI MABSPONSORED ADS0.52%$605,917325.8K
50ADAGADAGENE INCADS0.37%$435,072155.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$193M56May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$209M60Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$165M68Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$135M63Aug 15, 2025RESTATEMENTchanges · EDGAR ↗
Q1 2025$112M59May 16, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$133M59Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$146M56Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$115M50Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$117M53May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$101M52Feb 15, 202413F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.